Wu Li-Wei, Kao Tung-Wei, Lin Chien-Ming, Yang Hui-Fang, Sun Yu-Shan, Liaw Fang-Yih, Wang Chung-Ching, Peng Tao-Chun, Chen Wei-Liang
Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan (ROC) School of Medicine, National Defense Medical Center, Taipei, Taiwan (ROC) Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan (ROC) Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan (ROC).
Division of Family Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan (ROC) School of Medicine, National Defense Medical Center, Taipei, Taiwan (ROC) Division of Geriatric Medicine, Department of Family and Community Medicine, Tri-Service General Hospital, Taipei, Taiwan (ROC).
BMJ Open. 2016 May 23;6(5):e011186. doi: 10.1136/bmjopen-2016-011186.
Emerging evidence indicates that elevated serum lactic dehydrogenase (LDH) levels are associated with increased cardiovascular mortality, but the mechanisms for this relationship remain uncertain. Since metabolic syndrome (MetS) is correlated with a higher risk of cardiovascular complications, we investigated the joint association between serum LDH levels and all-cause mortality in the US general population with MetS.
Retrospective study.
The USA.
A retrospective observational study of 3872 adults with MetS and 7516 adults without MetS in the National Health and Nutrition Examination Survey III was performed.
Participants with and without MetS were both divided into 3 groups according to their serum LDH level. Multivariable Cox regression analyses and Kaplan-Meier survival probabilities were used to jointly relate all-cause, cardiovascular and cancer mortality risk to different serum LDH levels.
For all-cause mortality in participants with MetS, multivariable adjusted HRs were 1.006 (95% CI 0.837 to 1.210; p=0.947) for serum LDH of 149-176 U/L compared with 65-149 U/L, and 1.273 (95% CI 1.049 to 1.547; p=0.015) for serum LDH of 176-668 U/L compared with 65-149 U/L.
Results support a positive association between higher level of serum LDH and mortality from all causes in individuals with MetS.
新出现的证据表明，血清乳酸脱氢酶（LDH）水平升高与心血管疾病死亡率增加有关，但这种关系的机制仍不确定。由于代谢综合征（MetS）与心血管并发症风险较高相关，我们调查了美国患有MetS的普通人群中血清LDH水平与全因死亡率之间的联合关联。
回顾性研究。
美国。
对美国国家健康与营养检查调查III中3872名患有MetS的成年人和7516名未患有MetS的成年人进行了回顾性观察研究。
患有和未患有MetS的参与者均根据其血清LDH水平分为3组。采用多变量Cox回归分析和Kaplan-Meier生存概率来联合分析不同血清LDH水平与全因、心血管和癌症死亡率风险之间的关系。
对于患有MetS的参与者的全因死亡率，血清LDH为149 - 176 U/L与65 - 149 U/L相比，多变量调整后的风险比（HR）为1.006（95%置信区间0.837至1.210；p = 0.947）；血清LDH为176 - 668 U/L与65 - 149 U/L相比，多变量调整后的HR为1.273（95%置信区间1.049至1.547；p = 0.015）。
结果支持血清LDH水平升高与患有MetS的个体全因死亡率之间存在正相关。
